Process for manufacturing von Willebrand factor having a very high purity, largely devoid of antihaemophilic factor (fviiic), and von Willebrand factor thereby obtained as well as a pharmaceutical composition containing it.

The invention relates to a von Willebrand Factor manufacturing process. This process comprises the selective adsorption of factor VIIIc on the gel of a first chromatographic ion exchange, the von Willebrand factor being contained in the non-retained fraction, and is characterized in that treating the fraction not retained so as to selectively adsorb the von Willebrand factor on the gel of a second chromatography column which is subsequently desorbed by being obtained with a very high purity. The invention provides a von Willebrand factor of very high purity, largely devoid of antihaemophilic factor VIIIc, inactivators such as Tween and TNBP, as well as of the main plasma contaminants.